Education
About Us
Working with TipRanks
Follow Us
Clene (CLNN)
NASDAQ:CLNN
CLNN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.57 - $9.20
Previous CloseN/A
Volume48.08K
Average Volume (3M)50.51K
Market Cap
$22.27M
Enterprise Value$51.64M
Total Cash (Recent Filing)$12.15M
Total Debt (Recent Filing)$20.84M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 13, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding8,631,374
10 Day Avg. Volume72,817
30 Day Avg. Volume50,509
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)78.47
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit189.87
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$27.00Price Target Upside785.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Clene News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataClene shared new long-term survival data from cross-regimen post-hoc analyses comparing CNM-Au8 and zilucoplan, reinforcing CNM-Au8's survival benefits.
Financial PositionClene is well-positioned to raise capital due to the potential near-term NDA filing for CNM-Au8.
Regulatory ProgressClene's lead asset, CNM-Au8, has Orphan Drug Designation, which should qualify for Priority Review, potentially speeding up the approval process.
Bears Say
Cash ReservesClene ended the year with $12.2 million in cash, which management believes provides runway to fund ongoing operations through 2Q25.
Clinical Trial OutcomesRegimen A was prematurely halted for futility after zilucoplan was found to have a low probability of meaningfully slowing disease progression vs. placebo.
Regulatory ChallengesClene still has to conduct a confirmatory Phase 3 trial for the Accelerated Approval pathway, which introduces an additional step before potential approval.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $2.57 and its highest was $9.20 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is $22.27M.
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is May 13, 2025 which is in 39 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Mar 24, 2025. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$0.967 by -$0.623.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.92.
How many shares outstanding does Clene have?
Clene has 8,631,374 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$1.59 in its last earnings report, missing expectations of -$0.967. Following the earnings report the stock price went down -5.314%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
---
Clene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (785.25% Upside)
$27.00 (785.25% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $12.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.12%
12-Months-Change
Fundamentals
Return on Equity
-1738.36%
Trailing 12-Months
Asset Growth
-47.77%
Trailing 12-Months
Company Description
Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
---
CLNN Stock 12 Month Forecast
Average Price Target
$27.00
▲(785.25% Upside)
Technical Analysis
Best Analysts Covering CLNN
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-43.11%
reiterated a buy rating 11 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.11% per trade.
---